Consider This from NPR - Biden’s Push to Make Some of the Most Expensive Prescription Drugs Cheaper
The new prices that the federal government will eventually negotiate for these prescription drugs won't actually go into effect until 2026, and that's only if it doesn't get tied up in court with drugmakers. Six pharmaceutical companies who have filed lawsuits against the administration are calling these provisions unconstitutional.
Juana Summers speaks with NPR's pharmaceuticals correspondent Sydney Lupkin and Deepa Shivaram at the White House about the battle lines being drawn between the Biden Administration and pharmaceutical companies.
Learn more about sponsor message choices: podcastchoices.com/adchoices
NPR Privacy Policy
Consider This from NPR - Biden’s Push to Make Some of the Most Expensive Prescription Drugs Cheaper
The new prices that the federal government will eventually negotiate for these prescription drugs won't actually go into effect until 2026, and that's only if it doesn't get tied up in court with drugmakers. Six pharmaceutical companies who have filed lawsuits against the administration are calling these provisions unconstitutional.
Juana Summers speaks with NPR's pharmaceuticals correspondent Sydney Lupkin and Deepa Shivaram at the White House about the battle lines being drawn between the Biden Administration and pharmaceutical companies.
Learn more about sponsor message choices: podcastchoices.com/adchoices
NPR Privacy Policy
Consider This from NPR - Biden’s Push to Make Some of the Most Expensive Prescription Drugs Cheaper
The new prices that the federal government will eventually negotiate for these prescription drugs won't actually go into effect until 2026, and that's only if it doesn't get tied up in court with drugmakers. Six pharmaceutical companies who have filed lawsuits against the administration are calling these provisions unconstitutional.
Juana Summers speaks with NPR's pharmaceuticals correspondent Sydney Lupkin and Deepa Shivaram at the White House about the battle lines being drawn between the Biden Administration and pharmaceutical companies.
Learn more about sponsor message choices: podcastchoices.com/adchoices
NPR Privacy Policy
State of the World from NPR - Ukrainian civilians flee fighting on the eastern front
Learn more about sponsor message choices: podcastchoices.com/adchoices
NPR Privacy Policy
Reset with Sasha-Ann Simons - New Study: Expressive Writing Helps Treat PTSD
The Gist - I WAS WRONG: Louis C.K.
While Mike is on vacation, we are revisiting topics he was wrong about. Today we tackle Louis C.K. Back in 2017, the comedian was at the top of his game, when multiple women accused him of sexual misconduct. As the news swirled, Mike predicted that Louis could rehab his career and return to the pinnacle of comedy ... but those predictions did not come true. On today's show, how Mike got it wrong.
Produced by Joel Patterson and Corey Wara
Email us at thegist@mikepesca.com
To advertise on the show, visit: https://advertisecast.com/TheGist
Subscribe to The Gist Subscribe: https://subscribe.mikepesca.com/
Follow Mikes Substack at: Pesca Profundities | Mike Pesca | Substack
Learn more about your ad choices. Visit podcastchoices.com/adchoices
The Daily Signal - Rep. Steve Scalise Has Cancer, GOP Lawmakers Calls on Federal Bureaucrats to Return to in Person Work, Mayor Francis Suarez End White House Bid | Aug. 29
TOP NEWS | On today’s Daily Signal Top News, we break down:
- House Majority Leader Steve Scalise, a Republican from Louisiana, has cancer.
- The Biden administration announces 10 drugs that have been chosen for medicare price negotiations.
- Republican Iowa Sen. Joni Ernst wants federal bureaucrats to return to in-person work.
- Miami Republican Mayor Francis Suarez ends his bid for the White House.
Relevant Links
Listen to other podcasts from The Daily Signal: https://www.dailysignal.com/podcasts/
Get daily conservative news you can trust from our Morning Bell newsletter: DailySignal.com/morningbellsubscription
Listen to more Heritage podcasts: https://www.heritage.org/podcasts
Sign up for The Agenda newsletter — the lowdown on top issues conservatives need to know about each week: https://www.heritage.org/agenda
Hosted on Acast. See acast.com/privacy for more information.
Learn more about your ad choices. Visit megaphone.fm/adchoices
CoinDesk Podcast Network - THE HASH: Court Rules SEC Must Review Rejection of Grayscale’s Bitcoin ETF Bid, Bitcoin Jumps 5%
The most valuable crypto stories for Tuesday, August 29, 2023.
"The Hash" tackles today's hot topics, including a federal court ruling that the SEC must review its rejection of Grayscale Investments' attempt to convert the Grayscale Bitcoin Trust (GBTC) into an ETF. Bitcoin is surging on the news. Grayscale and CoinDesk are both owned by DCG. Separately, the SEC issued its first NFT-related enforcement action. And, some former FTX users are getting hit by a new phishing attack on their FTX-registered emails.
See also:
Bitcoin Jumps 5% on Grayscale Ruling, While Crypto-Related Stocks Soar More Than 10%
DCG Reaches Crucial In-Principle Deal With Genesis Creditors, Recoveries Could Be Up to 90%
FTX Customers Hit by 'Withdrawal' Phishing Mails After SIM Swap Attack
This episode has been edited by senior producer Michele Musso and the executive producer is Jared Schwartz. Our theme song is “Neon Beach.”
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.